CACLP 2023 is not just a platform for those 1,400 exhibitors to showcase their latest products and technologies, but also an opportunity for industry professionals to learn and network. CACLP 2023 will feature a wide range of new products, academic and enterprise activities to attract more than 30,000 visitors from all over the world.

Bio-economy is a new economic form based on the development progress and popular application of life science and biotechnology, and is an important part of the national economy.

Which segmentations will have a broader development prospect in the Chinese IVD field?

Recently, executives from multinational medical enterprises intensively visited China or revealed their plans to visit China. It is becoming a common question for most multinational medical businesses to explore how to support China's high-level opening up.

By the end of 2022, there were 1,033,000 medical and health institutions in China, including 37,000 hospitals. The medical and health institutions in China possessed 9.75 million beds, of which hospitals possessed 7.66 million and township health centers had 1.45 million.

Genetron Health said Friday that it has entered into an exclusive agreement with Jiangsu Fosun Pharmaceutical Sales, a subsidiary of Shanghai Fosun Pharmaceutical, to commercialize its minimal residual disease assay Seq-MRD.

On May 28, the website of the Chinese Center for Disease Control and Prevention published the "General Information on Adverse Reaction Monitoring of COVID-19 Vaccine Vaccination" jointly published by the center and the National Adverse Drug Reaction Monitoring Center.